New Delhi, June 14 (IANS) Australian researchers have launched a pioneering clinical trial that aims to combat aggressive cancers previously deemed untreatable.
The trial led by a team from the Australian National University (ANU) focussed on malignancies driven by the elusive MYC protein — a protein implicated in 70 per cent of human cancers –, Xinhua news agency reported.
The success of the trial could redefine treatment paradigms for aggressive malignancies globally, offering a template for tackling other molecularly complex diseases, said the team.
The study will test an experimental drug, PMR-116, designed to disrupt cancer growth mechanisms in patients with prostate, breast, ovarian, and blood cancers, or MYC-driven tumours.
The MYC protein is a key regulator of cell growth. It is often implicated in cancer, contributing to tumour development.
Led by the ANU and Canberra Health Services the trial adopts an innovative “basket” approach, grouping participants based on molecular biomarkers rather than cancer type.
This method streamlines research by targeting MYC through its downstream effects, meaning it blocks the processes MYC triggers in the cell rather than trying to block MYC itself, according to the study.
PMR-116, developed by ANU researchers and biotech firm Pimera Therapeutics, inhibits ribosomal biogenesis, a cellular process exploited by MYC-driven tumours.
“MYC is one of the most notorious cancer-causing genes, and tumours driven by MYC overexpression are often among the most aggressive and difficult to treat,” said hematologist and ANU professor Mark Polizzotto, who will lead the clinical trial.
“MYC has long been considered ‘undruggable,’ but early results of PMR-116 show promise in changing that perception,” he added.
The trial will enroll patients at major hospitals in Canberra, Melbourne, and Sydney starting in late 2025, prioritising those whose cancers resist standard therapies, said the research team.
ANU professor Ross Hannan, co-developer of PMR-116, highlighted that this approach represents a new direction in precision oncology, focusing on cancer’s molecular drivers instead of its location, potentially speeding up treatments for many patients worldwide.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
